John C. Grecula, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of precision delivery of radiation for patients with small cell lung cancer and advances that include prophylactic cranial radiotherapy, thoracic radiotherapy, and the use of PET-CT.
Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.
Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.
Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, discusses cardiac toxicities in cancer survivors, a new topic for the NCCN Survivorship Guidelines this year, and the need for more research on this important side effect, including prevention and surveillance.
Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, the “financial toxicities” of high drug prices, and what could and should be done about it.
